Announces the indefinite UK-wide ban on sale/supply of puberty blockers for under-18s (private and EEA/Swiss prescribers), in force 1 January 2025 with first review in 2027, on CHM advice (8 recommendations). Also documents: NHS stopped routine prescription March 2024; Tavistock GIDS managed closure March 2024; new regional services opened London/North West April 2024 and Bristol November 2024; NIHR puberty-blocker trial planned.
The Commission on Human Medicines (CHM) has provided independent expert advice that there is currently an unacceptable safety risk in the continued prescription of puberty blockers to children.
Announces the indefinite UK-wide ban on sale/supply of puberty blockers for under-18s (private and EEA/Swiss prescribers), in force 1 January 2025 with first review in 2027, on CHM advice (8 recommendations). Also documents: NHS stopped routine prescription March 2024; Tavistock GIDS managed closure March 2024; new regional services opened London/North West April 2024 and Bristol November 2024; NIHR puberty-blocker trial planned. Quotes from Wes Streeting, Prof Steve Cunningham (CHM), Dr Hilary Cass, James Palmer (NHS).